Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Neurobiol Dis. 2019 Jan 30;125:123–134. doi: 10.1016/j.nbd.2019.01.020

Figure 2.

Figure 2.

Combination (COMB) treatment significantly increased tight junction proteins expression in vitro in bEnd3 cells and in vivo in isolated mice brain microvessels compared to vehicle treated groups (control = CTRL), and etodolac (ETO) and/or α-tocopherol (Tph).

(a) Representative Western blot and densitometry analysis of ZO-1 and claudin-5 expression in bEnd3 cells. Cells were treated with 10μM of each compound for 24 h. Data represented as mean ± SD of 3 independent experiments with n=3 dishes/treatment/experiment. (b) Representative Western blot and densitometry analysis of ZO-1 and claudin-5 in vivo from microvessels isolated from 5XFAD mice brains. Microvessels were isolated from the homogenate of the right hemisphere of mice brains (n=5–6 mice). Mice were treated with ETO, Tph or COMB at 10 mg/kg/day each for 30 days. Data represented as mean ± SEM of n=5–6 mice per group. ns = not significant; * p < 0.05, ** p < 0.01, *** p < 0.001 compared to CTRL; # p < 0.05, ## p < 0.01 represent COMB compared to ETO alone; @ p < 0.05, @@ p < 0.01, @@@ p < 0.001represent COMB compared to Tph alone.